Cancer patients on PD-1 inhibitors at risk of arthritis

Rheumatic adverse events 'relatively common' on the treatment, researchers say

Patients who respond well to programmed cell death protein 1 (PD-1) inhibitor therapy for cancer, may be at increased risk of developing arthritis as an adverse effect, an Australian study suggests.